Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SALUTENSIN-DEMI vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Hydrochlorothiazide: 6-15 hours (terminal), clinical effect lasts 6-12 hours; Reserpine: 50-100 hours (terminal), with prolonged action due to irreversible vesicular depletion
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Hydroflumethiazide is minimally metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal: hydrochlorothiazide 70% unchanged, reserpine <1% unchanged; fecal: reserpine ~6% as metabolites
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Hydrochlorothiazide: 40-68% (primarily to albumin); Reserpine: approximately 40% (to albumin and α1-acid glycoprotein)
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Hydrochlorothiazide: 0.2-0.4 L/kg (distributes in extracellular fluid); Reserpine: 5-10 L/kg (extensive tissue distribution, high affinity for adrenergic neurons)
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: hydrochlorothiazide 65-75%; reserpine 30-50% (extensive first-pass metabolism)
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in GFR <30 m L/min. For GFR 30-50 m L/min: use maximum 1 tablet daily; monitor electrolytes and renal function.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., every other day). Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for pediatric use due to lack of safety and efficacy data; alternative agents preferred.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start with 0.5 tablet (7.5 mg hydrochlorothiazide + 0.0375 mg clonidine) once daily; monitor for orthostatic hypotension, electrolyte imbalance, and renal function; avoid in patients with high frailty.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None.
None
Electrolyte imbalances (hypokalemia, hyponatremia),Orthostatic hypotension,Depression (reserpine component),Potential for increased risk of non-melanoma skin cancer with thiazide diuretics,May exacerbate systemic lupus erythematosus
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Known hypersensitivity to sulfonamide-derived drugs (hydroflumethiazide),Anuria,History of mental depression (reserpine-containing products),Active peptic ulcer or ulcerative colitis,Concomitant use with MAO inhibitors
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, leafy greens) as thiazide can cause potassium loss; however, reserpine may increase potassium retention. Maintain balanced diet. Limit sodium intake to control blood pressure. Avoid grapefruit juice as it may increase reserpine absorption.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Possible risk of congenital malformations based on animal studies; human data limited. Second and third trimesters: Fetal hypotension, renal dysfunction, oligohydramnios, skull ossification delay. Avoid use unless benefit outweighs risk.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excreted in breast milk; M/P ratio not reported. Risk of infant hypotension and renal impairment. Use caution, monitor infant blood pressure and renal function.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Dose may need reduction due to increased volume of distribution and altered drug clearance. Adjust based on clinical response and maternal blood pressure. Monitor for hypotension and electrolyte imbalance.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Salutensin-demi contains reserpine (rauwolfia alkaloid) and a thiazide diuretic. Monitor for depression, nasal stuffiness, and hypotension. Avoid concurrent MAOIs. Use with caution in patients with a history of peptic ulcer disease due to increased gastric acid secretion from reserpine.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed, usually once daily in the morning.,Avoid sudden discontinuation; taper dose to prevent rebound hypertension.,Report signs of depression, nightmares, or severe drowsiness.,May cause dizziness upon standing; rise slowly from sitting or lying.,Notify your doctor if you develop abdominal pain, black stools, or unusual bleeding.,Avoid alcohol, which can increase drowsiness and hypotension.,Take with food or milk to lessen stomach upset.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SALUTENSIN-DEMI vs ALDORIL D30, answered by our medical review team.
SALUTENSIN-DEMI is a Antihypertensive Combination that works by Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SALUTENSIN-DEMI and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SALUTENSIN-DEMI is: 1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SALUTENSIN-DEMI and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SALUTENSIN-DEMI is classified as Category C. First trimester: Possible risk of congenital malformations based on animal studies; human data limited. Second and third trimesters: Fetal hypotension, renal dysfunction, oligohydr. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.